| Chronic hepatitis C virus (HCV) infection remains a
public health problem worldwide. Traditional interferon-based
therapy leads to viral eradication in less than 50% of treated
patients. New treatment using direct-acting antiviral drugs has
significantly increased the cure rate. These new drugs directly
interfere with different steps of the HCV replication cycle. Thus,
existing models that do not consider within-cell processes may not
be optimal in analyzing data from patients treated with new drugs.
In this talk, I will review mathematical models used to study HCV
dynamics under traditional therapy and discuss recent advances in
the development of multi-scale models for new drugs. I will address
model analysis, approximation, comparison with patient data, and the
implications for developing new treatment strategies for hepatitis
C. |